Journal of Experimental & Clinical Cancer Research

Article	Citations
Chemotherapy-induced PTEN-L secretion promotes the selection of PTEN-deficient tumor cells	327
The potential of swine pseudorabies virus attenuated vaccine for oncolytic therapy against malignant tumors	273
Correction: Osteoglycin (OGN) reverses epithelial to mesenchymal transition and invasiveness in colorectal cancer via EGFR/Akt pathway	257
Retraction Note: Tripartite motif-containing 14 (TRIM14) promotes epithelial-mesenchymal transition via ZEB2 in glioblastoma cells	251
Correction: ZEB1-mediated biogenesis of circnipbl sustains the metastasis of bladder cancer via Wnt/β-catenin pathway	244
Retraction Note: TRIM11 overexpression promotes proliferation, migration and invasion of lung cancer cells	233
CRISPR-Cas9 knockout screening identifies KIAA1429 as an essential gene in Ewing sarcoma	191
Targeting homologous recombination deficiency in uterine leiomyosarcoma	188
Ropivacaine as a novel AKT1 specific inhibitor regulates the stemness of breast cancer	188
Pyrotinib targeted EGFR/GRP78 mediated cell apoptosis in high EGFR gene copy number gastric cancer	166
LncRNA MILIP links YBX1 to translational activation of Snai1 and promotes metastasis in clear cell renal cell carcinoma	154
FOXD1-dependent RalA-ANXA2-Src complex promotes CTC formation in breast cancer	152
The RP11-417E7.1/THBS2 signaling pathway promotes colorectal cancer metastasis by activating the Wnt/β-catenin pathway and facilitating exosome-mediated M2 macrophage polarization	147
Cell-of-origin and genetic drivers define advanced bladder cancer subtypes and potential therapeutic response in mouse models	145
Targeting FAM83D triggers tumor cell senescence via cGAS-STING signaling activation and reprograms TAMs to combat glioma	145
Regulatory role of lncH19 in RAC1 alternative splicing: implication for RAC1B expression in colorectal cancer	144
The importance of being CAFs (in cancer resistance to targeted therapies)	129
HES1 inhibition overcomes CDK4/6 inhibitor resistance by targeting cancer stemness in lung adenocarcinoma	122
Cell therapy using ex vivo reprogrammed macrophages enhances antitumor immune responses in melanoma	120
HERC2 promotes inflammation-driven cancer stemness and immune evasion in hepatocellular carcinoma by activating STAT3 pathway	114
Correction: circular RNA circATP9A promotes non-small cell Lung cancer progression by interacting with HuR and by promoting extracellular vesicles-mediated macrophage M2 polarization	114
Novel APLNR antagonist candesartan induces tumor vascular normalization through ROS/cGAS/STING axis and augmented sunitinib response in breast cancer	113
M2 macrophage-secreted KYNU promotes stemness remodeling and malignant behavior in endometrial cancer via the SOD2-mtROS-ERO1α-UPRER axis	110
TRIM6 ablation reverses ICB resistance in MSS gastric cancer by unleashing cGAS-STING-dependent antitumor immunity	107
tRNA-derived fragment tRF-24 drives CELF1 phase separation to promote oncogenic splicing in esophageal squamous cell carcinoma	106

cGAS-STING pathway regulated by spatiotemporal heterogeneity of tumor microenvironment and precision therapy strategies in lung cancer	104
The RNA methyltransferase METTL16 enhances cholangiocarcinoma growth through PRDM15-mediated FGFR4 expression	102
CD28/PD1 co-expression: dual impact on CD8+ T cells in peripheral blood and tumor tissue, and its significance in NSCLC patients' survival and ICB response	101
NK cell-triggered CCL5/IFNγ-CXCL9/10 axis underlies the clinical efficacy of neoadjuvant anti-HER2 antibodies in breast cancer	100
Targeting the HLA-E–NKG2A axis in combination with MS-275 enhances NK cell-based immunotherapy against DMG	99
EIF4A3-mediated biogenesis of circSTX6 promotes bladder cancer metastasis and cisplatin resistance	99
SEC23A confers ER stress resistance in gastric cancer by forming the ER stress-SEC23A-autophagy negative feedback loop	98
Combination of dual JAK/HDAC inhibitor with regorafenib synergistically reduces tumor growth, metastasis, and regorafenib-induced toxicity in colorectal cancer	96
Targeting PEG10 as a novel therapeutic approach to overcome CDK4/6 inhibitor resistance in breast cancer	94
The DCDC2/ENO1 axis promotes tumor progression and immune evasion in intrahepatic cholangiocarcinoma via activating FGL1-LAG3 checkpoint	94
The neuronal protein Neuroligin 1 promotes colorectal cancer progression by modulating the APC/β-catenin pathway	94
TWIST1 bridges p53 and MDM2 and impairs the efficacy of MDM2 inhibitors	91
Oridonin promotes endoplasmic reticulum stress via TP53-repressed TCF4 transactivation in colorectal cancer	90
Cancer-associated fibroblast-derived circKLHL24 drives perineural invasion in pancreatic cancer via dual regulation of the sec31a-CXCL12 axis	90
Circulating CD137⁺Treg cells and LOX-1⁺PMN-MDSCs as biomarkers of immunotherapy resistance in (R/M) HNSCC patients	88
The FGF/FGFR/c-Myc axis as a promising therapeutic target in multiple myeloma	86
CircFOXK2 promotes hepatocellular carcinoma progression and leads to a poor clinical prognosis via regulating the Warburg effect	84
CCNY-mediated phosphorylation and TET2-BACH1-driven DNA demethylation activate PRC1 to augment NSCLC progression	84
LncRNA FTO-IT1 promotes glycolysis and progression of hepatocellular carcinoma through modulating FTO-mediated N6-methyladenosine modification on GLUT1 and PKM2	83
Plasma-derived extracellular vesicles miR-335–5p as potential diagnostic biomarkers for fusion-positive rhabdomyosarcoma	82
Correction: Deliberation concerning the role of M1-type macrophage subset in oral carcinogenesis	82
Inhibition of RACGAP1 sensitizes triple-negative breast cancer cells to ferroptosis by regulating CPT1A-dependent fatty acid metabolism	82
Correction: Synthetic tetracycline-controllable shRNA targeting long non-coding RNA HOXD-AS1 inhibits the progression of bladder cancer	82
Correction: LncRNA-mediated DNA methylation: an emerging mechanism in cancer and beyond	81
Targeting ATR offers multifaceted treatment strategies involving RAD51-mediated compensatory DNA repair in bladder cancer	81
Multiple mechanisms and applications of tertiary lymphoid structures and immune checkpoint blockade	81
CRISPR knockout screens reveal JUN as the master mediator of resistance to MAPK inhibition in KRAS-mutant pancreatic cancer	81
Bridging phenotype and function in bladder cancer using immuno-competent organoids and ex vivo drug screening	81
USP43 promotes gemcitabine resistance by regulating cholesterol homeostasis through E2F1 stabilization in bladder cancer	80
NRGN inhibits CD8⁺ T cell effector function by downregulating MHC-I expression through the FMR1–IRF8 axis in hepatocellular carcinoma	77
CSRP2 promotes the glioblastoma mesenchymal phenotype via p130Cas-mediated NF-κB and MAPK pathways	77
Irradiation induces DJ-1 secretion from esophageal squamous cell carcinoma cells to accelerate metastasis of bystander cells via a TGF-β1 positive feedback loop	76
Mechanism of cancer-associated fibroblast-driven thyroid cancer dedifferentiation via the ZFP57-PKM2 axis-mediated lactate secretion and therapeutic intervention with resveratrol​	76
Toosendanin targeting eEF2 impedes Topoisomerase I & II protein translation to suppress esophageal squamous cell carcinoma growth	75
Blockade of αvβ6 and αvβ8 integrins with a chromogranin A-derived peptide inhibits TGFβ activation in tumors and suppresses tumor growth	75
The reprogramming impact of SMAC-mimetic on glioblastoma stem cells and the immune tumor microenvironment evolution	74
Genome-wide CRISPR screening identifies PHF8 as an effective therapeutic target for KRAS- or BRAF-mutant colorectal cancers	74
MUC20 regulated by extrachromosomal circular DNA attenuates proteasome inhibitor resistance of multiple myeloma by modulating cuproptosis	74
MiR-494 induces metabolic changes through G6pc targeting and modulates sorafenib response in hepatocellular carcinoma	73
Precision immune regulation in KRAS-mutated cancers: the final piece of the puzzle?	73
Acute myeloid leukemia: from NGS, through scRNA-seq, to CAR-T. dissect cancer heterogeneity and tailor the treatment	73
Cystine/glutamate antiporter xCT deficiency reduces metastasis without impairing immune system function in breast cancer mouse models	73
Targeting the CCL5/CCR5 axis in tumor-stromal crosstalk to overcome cisplatin resistance in neuroendocrine prostate cancer	72
Detection and characterization of pancreatic and biliary tract cancers using cell-free DNA fragmentomics	72
Targeting E2F8 sensitizes gemcitabine-resistant gallbladder cancer to PARP inhibitors by disrupting RRM2-driven DNA repair	72
C-FOS promotes the formation of neutrophil extracellular traps and the recruitment of neutrophils in lung metastasis of triple-negative breast cancer	71
The KLF16/MYC feedback loop is a therapeutic target in bladder cancer	71
Unbiased profiling of translational landscape reveals TNFR2 as a translation-dependent vulnerability in colorectal cancer	71
Correction: Intravesical instillation-based mTOR-STAT3 dual targeting for bladder cancer treatment	70
Tumor microenvironment remodeling by STING agonism sensitizes endothelial cells to cytotoxic anti-PD-L1/L2 antibody	70

Kremen2 drives the progression of non-small cell lung cancer by preventing SOCS3-mediated degradation of EGFR	70
A blood-based liquid biopsy analyzing soluble immune checkpoints and cytokines identifies distinct neuroendocrine tumors	69
Correction: Targeting FTO induces colorectal cancer ferroptotic cell death by decreasing SLC7A11/ GPX4 expression	69
Ficolin 3 promotes ferroptosis in HCC by downregulating IR/SREBP axis-mediated MUFA synthesis	68
Harnessing cancer stem cell-derived exosomes to improve cancer therapy	67
PARP1-targeted fluorescence molecular endoscopy as novel tool for early detection of esophageal dysplasia and adenocarcinoma	66
Correction: MiR-423-5p is a metabolic and growth tuner in hepatocellular carcinoma via MALAT-1 and mitochondrial interaction	66
Neoadjuvant toripalimab combined with gemcitabine and cisplatin in resectable locally advanced head and neck squamous cell carcinoma (NeoTGP01): An open label, single-arm, phase Ib clinical trial	65
PARD3 drives tumorigenesis through activating Sonic Hedgehog signalling in tumour-initiating cells in liver cancer	65
Emerging frontiers in androgen receptor research for prostate Cancer: insights from the 2nd international androgen receptor Symposium	65
TSP50 facilitates breast cancer stem cell-like properties maintenance and epithelial-mesenchymal transition via PI3K p110α mediated activation of AKT signaling pathway	65
Regulation of the Hippo/YAP axis by CXCR7 in the tumorigenesis of gastric cancer	64
USP1 driven mitotic dysregulation and PLK1 stabilization confer Lenvatinib resistance in hepatocellular carcinoma	64
Tumorigenesis of basal muscle invasive bladder cancer was mediated by PTEN protein degradation resulting from SNHG1 upregulation	64
Connecting the dots: investigating the link between environmental, genetic, and epigenetic influences in metabolomic alterations in oral squamous cell carcinoma	63
Novel cancer treatment paradigm targeting hypoxia-induced factor in conjunction with current therapies to overcome resistance	63
Mechanisms of neural infiltration-mediated tumor metabolic reprogramming impacting immunotherapy efficacy in non-small cell lung cancer	63
PCSK9 facilitates melanoma pathogenesis via a network regulating tumor immunity	63
Efficacy of CAR-T immunotherapy in MET overexpressing tumors not eligible for anti-MET targeted therapy	60
Epstein-Barr viral product-containing exosomes promote fibrosis and nasopharyngeal carcinoma progression through activation of YAP1/FAPα signaling in fibroblasts	59
Cellular senescence in cancer: clinical detection and prognostic implications	59
Exosomal long noncoding RNA MLETA1 promotes tumor progression and metastasis by regulating the miR-186-5p/EGFR and miR-497-5p/IGF1R axes in non-small cell lung cancer	59
METTL3 recruiting M2-type immunosuppressed macrophages by targeting m6A-SNAIL-CXCL2 axis to promote colorectal cancer pulmonary metastasis	58
LINC00460/miR-186-3p/MYC feedback loop facilitates colorectal cancer immune escape by enhancing CD47 and PD-L1 expressions	58
MiR-7 inhibits progression of glioblastoma by impairing autophagy resolution, energy metabolism and ECM remodeling	58
Platform combining statistical modeling and patient-derived organoids to facilitate personalized treatment of colorectal carcinoma	58
Targeting mTOR and survivin concurrently potentiates radiation therapy in renal cell carcinoma by suppressing DNA damage repair and amplifying mitotic catastrophe	57
Correction: Colorectal carcinoma peritoneal metastases‑derived organoids: results and perspective of a model for tailoring hyperthermic intraperitoneal chemotherapy from bench‑to‑bedside	56
Circular RNA circATP9A promotes non-small cell lung cancer progression by interacting with HuR and by promoting extracellular vesicles-mediated macrophage M2 polarization	56
Protein homeostasis maintained by HOOK1 levels promotes the tumorigenic and stemness properties of ovarian cancer cells through reticulum stress and autophagy	55
NOTCH3 regulates myofibroblastic CAF differentiation via the P62–ROS signaling axis to promote bladder cancer progression	55
Retraction Note: Integrin-β5, a miR-185-targeted gene, promotes hepatocellular carcinoma tumorigenesis by regulating β-catenin stability	55
LncRNA AL139294.1 can be transported by extracellular vesicles to promote the oncogenic behaviour of recipient cells through activation of the Wnt and NF-κB2 pathways in non-small-cell lung cancer	55
Retraction Note: LncMAPK6 drives MAPK6 expressionand liver TIC self-renewal	55
CDK1 drives SOX9-mediated chemotherapeutic resistance in gastric cancer	54
Neurogenic inducers inhibit the proliferation of pancreatic cancer by promoting tumor cell transdifferentiation	54
FGD3 mediates lytic cell death, enhancing efficacy and immunogenicity of chemotherapy agents in breast cancer	54
Predicting response to immunotherapy in gastric cancer via assessing perineural invasion-mediated inflammation in tumor microenvironment	54
CRISPR/Cas9: a powerful tool in colorectal cancer research	53
Human iPSC-derived and conventional cancer models in precision oncology: advancing patient-specific therapies from bench to bedside	53
PXDN regulated by WTAP/YTHDF1-mediated m6A modification activates PI3K/AKT signaling pathway through extracellular matrix remodeling to promote progression in nasopharyngeal carcinoma	53
Gastric cancer cells-derived exosomal miR-151a-5p induces an immunosuppressive microenvironment through promoting LAG3+TAMs infiltration	53
HERC5 downregulation in non-small cell lung cancer is associated with altered energy metabolism and metastasis	53
A combination of PD-1 and TIGIT immune checkpoint inhibitors elicits a strong anti-tumour response in mesothelioma	52
CD70 CAR-T cells empowered by TS-2021 through ex vivo transduction show potent antitumor efficacy against glioblastoma	52
The crosstalk between immune cells and tumor pyroptosis: advancing cancer immunotherapy strategies	52
Small extracellular vesicles: messengers at the service of breast cancer agenda in the primary and distant microenvironments	52
YTHDC1 is downregulated by the YY1/HDAC2 complex and controls the sensitivity of ccRCC to sunitinib by targeting the ANXA1-MAPK pathway	52
Non-canonical activation of MAPK signaling by the lncRNA ASH1L-AS1-encoded microprotein APPLE through inhibition of PP1/PP2A-mediated ERK1/2 dephosphorylation in hepatocellular carcinoma	51
CHD1L in cancer and beyond: structure, oncogenic functions, and therapeutic potential	51
NSD2 upregulation is driven by high-risk HPV E6/E7 and disrupts epithelial differentiation in HPV-associated head and neck cancer	51
Novel MAFG-METTL14-SCD1 axis regulates lipid metabolism mediating choroidal melanoma distant metastasis	50
CircRNF10 triggers a positive feedback loop to facilitate progression of glioblastoma via redeploying the ferroptosis defense in GSCs	50
Multi-layer stratified oncology platform utilizing transcriptomics, prostate cancer organoids, and modeling of drug response	50
Auranofin repurposing for lung and pancreatic cancer: low CA12 expression as a marker of sensitivity in patient-derived organoids, with potentiated efficacy by AKT inhibition	49
Dual CDK and MEK Inhibition potentiates CD8+ T cell-mediated antitumor immunity by inducing pyroptotic cell death in high-mutational head and neck cancer	49
Novel Pt@PCN-Cu-induced cuproptosis amplifies αPD-L1 immunotherapy in pancreatic ductal adenocarcinoma through mitochondrial HK2-mediated PD-L1 upregulation	48
Three-dimensional environment sensitizes pancreatic cancer cells to the anti-proliferative effect of budesonide by reprogramming energy metabolism	48
Transcriptomics-based liquid biopsy panel for early non-invasive identification of peritoneal recurrence and micrometastasis in locally advanced gastric cancer	48
CircLRFN5 inhibits the progression of glioblastoma via PRRX2/GCH1 mediated ferroptosis	48
CircZNF215 promotes tumor growth and metastasis through inactivation of the PTEN/AKT pathway in intrahepatic cholangiocarcinoma	48
LAMC2 marks a tumor-initiating cell population with an aggressive signature in pancreatic cancer	47
RETRACTED ARTICLE: N6-methyladenosine modification of circMARK2 enhances cytoplasmic export and stabilizes LIN28B, contributing to the progression of Wilms tumor	47
Tailored FcγR blockade enhances immune checkpoint therapy and overcomes resistance	47
A glutamine tug-of-war between cancer and immune cells: recent advances in unraveling the ongoing battle	47
Extracellular vesicles activated cancer-associated fibroblasts promote lung cancer metastasis through mitophagy and mtDNA transfer	47
Autocrine regulation of tumor cell repopulation by Hsp70-HMGB1 alarmin complex	46
ECM-Induced IL-23 Drives Immune Suppression in Breast Cancer via Regulating PD-1 on Tregs	46
miR-92a-1-5p enriched prostate cancer extracellular vesicles regulate osteoclast function via MAPK1 and FoxO1	46
PRMT5 inhibition has a potent anti-tumor activity against adenoid cystic carcinoma of salivary glands	46
Correction: CD36 enrichment in HER2-positive mesenchymal stem cells drives therapy refractoriness in breast cancer	45
Notch1 blockade by a novel, selective anti-Notch1 neutralizing antibody improves immunotherapy efficacy in melanoma by promoting an inflamed TME	45
NK-A 17E-233I: a novel competitive inhibitor of human dihydroorotate dehydrogenase (DHODH) for cancer therapy	45
Isolation and characterization of two newly established thymoma PDXs from two relapses of the same patient: a new tool to investigate thymic malignancies	45
Pathogenic mitochondrial DNA variants are associated with response to anti-VEGF therapy in ovarian cancer PDX models	45
Long-term exposure to house dust mites accelerates lung cancer development in mice	45
Correction: SH3GLB1-related autophagy mediates mitochondrial metabolism to acquire resistance against temozolomide in glioblastoma	45
Retraction Note: Yes-associated protein (YAP) binds to HIF-1α and sustains HIF-1α protein stability to promote hepatocellular carcinoma cell glycolysis under hypoxic stress	45
LARS promotes osteosarcoma proliferation through leucine-dependent PRIM2 translation and DNA replication activation	44
Iron diminishes immunosuppressive macrophages and enhances anti-PD-1 immunotherapy in breast cancer models	44

Recapitulating the tumour microenvironment: advancing personalised radiation therapy through organoid technology	44
Correction: MKRN1 promotes colorectal cancer metastasis by activating the TGF-β signalling pathway through SNIP1 protein degradation	44
Progesterone boosts abiraterone-driven target and NK cell therapies against glioblastoma	43
Biopsy RNA-seq captures TROP-2–linked migration and clonal resistance to forecast aggressiveness in metastatic melanoma	43
Cryoablation-induced neutrophil Ca2+ elevation and NET formation exacerbate immune escape in colorectal cancer liver metastasis	43
Landscape of immune-related signatures induced by targeting of different epigenetic regulators in melanoma: implications for immunotherapy	43
Antibody drug conjugates: hitting the mark in pancreatic cancer?	43
Endoplasmic reticulum-localized circular RNA FAM13B restrains nasopharyngeal carcinoma lymphatic metastasis through downregulating XBP1	43
Tumor-associated macrophage-derived exosomes LINC01592 induce the immune escape of esophageal cancer by decreasing MHC-I surface expression	43
TSPAN18 facilitates bone metastasis of prostate cancer by protecting STIM1 from TRIM32-mediated ubiquitination	42
The lncRNA HOTAIR: a pleiotropic regulator of epithelial cell plasticity	42
Patterns of toxicity burden for FDA-approved immune checkpoint inhibitors in the United States	42
Chronic stress accelerates glioblastoma progression via DRD2/ERK/β-catenin axis and Dopamine/ERK/TH positive feedback loop	42
S100A9+CD14+ monocytes contribute to anti-PD-1 immunotherapy resistance in advanced hepatocellular carcinoma by attenuating T cell-mediated antitumor function	42
HHLA2 activates c-Met and identifies patients for targeted therapy in hepatocellular carcinoma	42
CCR8 antagonist suppresses liver cancer progression via turning tumor-infiltrating Tregs into less immunosuppressive phenotype	41
HIF-2α/LINC02609/APOL1-mediated lipid storage promotes endoplasmic reticulum homeostasis and regulates tumor progression in clear-cell renal cell carcinoma	41
LATS1/2 loss promote tumor immune evasion in endometrial cancer through downregulating MHC-I expression	41
Augmented ERO1α upon mTORC1 activation induces ferroptosis resistance and tumor progression via upregulation of SLC7A11	41
Cancer-educated mammary adipose tissue-derived stromal/stem cells in obesity and breast cancer: spatial regulation and function	41
Correction: albumin-bound paclitaxel augment temozolomide treatment sensitivity of glioblastoma cells by disrupting DNA damage repair and promoting ferroptosis	41
IL-33 stimulates the anticancer activities of eosinophils through extracellular vesicle-driven reprogramming of tumor cells	41
Correction: Comparing Xenium 5K and Visium HD data from identical tissue slide at a pathological perspective	40
S1PR1 suppresses lung adenocarcinoma progression through p-STAT1/miR-30c-5 p/FOXA1 pathway	40
The TP53-activated E3 ligase RNF144B is a tumour suppressor that prevents genomic instability	40
Cancer-associated fibroblasts as a potential novel liquid biopsy marker in cancer patients	40
Biopiezoelectric-based nanomaterials; a promising strategy in cancer therapy	40
Circular RNA-based HPV16 therapeutic vaccine elicits potent and durable antitumor immunity	40
RNF31 represses cell progression and immune evasion via YAP/PD-L1 suppression in triple negative breast Cancer	40
Transforming tumor microenvironments: nanotechnology and gene therapy in cellular signaling and epigenetic insight into chemo-resistance	39
A chimeric antigen receptor tailored to integrate complementary activation signals potentiates the antitumor activity of NK cells	39
o8G-modified circKIAA1797 promotes lung cancer development by inhibiting cuproptosis	39
HSPA4 upregulation induces immune evasion via ALKBH5/CD58 axis in gastric cancer	39
METTL16 promotes glycolytic metabolism reprogramming and colorectal cancer progression	38
Preoperative liquid biopsy transcriptomic panel for risk assessment of lymph node metastasis in T1 gastric cancer	38
Reprogramming the breast tumor immune microenvironment: cold-to-hot transition for enhanced immunotherapy	38
Cancer-associated fibroblasts-derived CXCL12 enhances immune escape of bladder cancer through inhibiting P62-mediated autophagic degradation of PDL1	38
Oncometabolite D-2HG drives tumor metastasis and protumoral macrophage polarization by targeting FTO/m6A/ANGPTL4/integrin axis in triple-negative breast cancer	38
Correction: Inhibition of autophagy enhances the antitumor efficacy of T/CAR T cell against neuroblastoma	37
Correction: The BRD4 inhibitor JQ1 augments the antitumor efficacy of abemaciclib in preclinical models of gastric carcinoma	37
Editorial expression of concern: ERRα suppression enhances the cytotoxicity of the MEK inhibitor trametinib against colon cancer cells	37
Correction: Long non-coding RNA DANCR promotes malignant phenotypes of bladder cancer cells by modulating the miR-149/MSI2 axis as a ceRNA	37
Correction: TSPAN18 facilitates bone metastasis of prostate cancer by protecting STIM1 from TRIM32-mediated ubiquitination	37
Retraction Note: Transcriptional repression of SOCS3 mediated by IL-6/STAT3 signaling via DNMT1 promotes pancreatic cancer growth and metastasis	36
Colorectal carcinoma peritoneal metastases-derived organoids: results and perspective of a model for tailoring hyperthermic intraperitoneal chemotherapy from bench-to-bedside	36
Synergistic intravesical instillation for bladder cancer: CRISPR-Cas13a and fenbendazole combination therapy	36
Transfection with Plasmid-Encoding lncRNA-SLERCC nanoparticle-mediated delivery suppressed tumor progression in renal cell carcinoma	36
Retraction Note: Downregulation of lncRNA ZNF582-AS1 due to DNA hypermethylation promotes clear cell renal cell carcinoma growth and metastasis by regulating the N(6)- methyladenosine modification of	36
Correction: Anti-tumor effects of ONC201 in combination with VEGF-inhibitors significantly impacts colorectal cancer growth and survival in vivo through complementary non-overlapping mechanisms	36
AGD1/USP10/METTL13 complexes enhance cancer stem cells proliferation and diminish the therapeutic effect of docetaxel via CD44 m6A modification in castration resistant prostate cancer	36
Nanocarrier-mediated targeting of NF-κB and JAK/STAT signaling pathways in hepatocellular carcinoma: mechanisms and therapeutic strategies	35
Unveiling the role of osteosarcoma-derived secretome in premetastatic lung remodelling	35
FASN inhibits ferroptosis in breast cancer via USP5 palmitoylation-dependent regulation of GPX4 deubiquitination	35
hnRNPA1-SF3B3 interaction drives radioresistance in oral squamous cell carcinoma by modulating MARF1 alternative splicing isoforms	35
Galectin-3 induces pathogenic immunosuppressive macrophages through interaction with TREM2 in lung cancer	35
Flavokawain A is a natural inhibitor of PRMT5 in bladder cancer	35
Correction: UFM1 suppresses invasive activities of gastric cancer cells by attenuating the expression of PDK1 through PI3K/AKT signaling	35
VSIG4+ tumor-associated macrophages mediate neutrophil infiltration and impair antigen-specific immunity in aggressive cancers through epigenetic regulation of SPP1	35
Examining the evidence for mutual modulation between m6A modification and circular RNAs: current knowledge and future prospects	35
STUB1-mediated K63-linked ubiquitination of UHRF1 promotes the progression of cholangiocarcinoma by maintaining DNA hypermethylation of PLA2G2A	34
LINC00240 in the 6p22.1 risk locus promotes gastric cancer progression through USP10-mediated DDX21 stabilization	34
Carboxylesterase 1 is a core metabolic vulnerability of platinum-resistant high-grade serous ovarian carcinoma	34
Baseline levels and dynamic changes of cfDNA, tumor fraction and mutations to anticipate the clinical course of small cell lung cancer (SCLC) patients treated with first-line atezolizumab and chemothe	34
Targeting tumor-associated macrophages to overcome immune checkpoint inhibitor resistance in hepatocellular carcinoma	34
Proteomic profiling identifies a stromal TGF-β1/podoplanin axis as a driver of colorectal cancer progression	34
A first-in-class inhibitor of HSP110 to potentiate XPO1-targeted therapy in primary mediastinal B-cell lymphoma and classical Hodgkin lymphoma	34
From paradox to target: IFN-β hijacks MEK signaling to drive a cell death-evading dormant phenotype in colorectal cancer	34
Targeting the radiation-induced ARv7-mediated circNHS/miR-512-5p/XRCC5 signaling with Quercetin increases prostate cancer radiosensitivity	34
Involvement of lncRNAs in cancer cells migration, invasion and metastasis: cytoskeleton and ECM crosstalk	34
COL10A1+ fibroblasts promote colorectal cancer metastasis and M2 macrophage polarization with pan-cancer relevance	34
Amino acid metabolism reprogramming: shedding new light on T cell anti-tumor immunity	34
Ginseng-derived nanoparticles reprogram macrophages to regulate arginase-1 release for ameliorating T cell exhaustion in tumor microenvironment	34
Correction: PSMD9 promotes the malignant progression of hepatocellular carcinoma by interacting with c-Cbl to activate EGFR signaling and recycling	33
An IgE antibody targeting HER2 identified by clonal selection restricts breast cancer growth via immune-stimulating activities	33
Correction: Inhibition of MTA1 by ERα contributes to protection hepatocellular carcinoma from tumor proliferation and metastasis	33
Correction: Loss of LKB1 disrupts breast epithelial cell polarity and promotes breast cancer metastasis and invasion	33
Stroma-derived miR-214 coordinates tumor dissemination	33
Correction: Integrin-linked kinase-frizzled 7 interaction maintains cancer stem cells to drive platinum resistance in ovarian cancer	33
Correction: The epigenetic downregulation of LncGHRLOS mediated by RNA m6A methylase ZCCHC4 promotes colorectal cancer tumorigenesis	33
RETSAT associates with DDX39B to promote fork restarting and resistance to gemcitabine based chemotherapy in pancreatic ductal adenocarcinoma	33
HES1-mediated down-regulation of miR-138 sustains NOTCH1 activation and promotes proliferation and invasion in renal cell carcinoma	32
SGSS05-NS3, a covalent SETD8 inhibitor that activates p53 pathway in neuroblastoma	32
MAGOH promotes gastric cancer progression via hnRNPA1 expression inhibition-mediated RONΔ160/PI3K/AKT signaling pathway activation	32
The cross-talk between the macro and micro-environment in precursor lesions of pancreatic cancer leads to new and promising circulating biomarkers	32
Biological and clinical impact of membrane EGFR expression in a subgroup of OC patients from the phase IV ovarian cancer MITO-16A/MANGO-OV2A trial	32
SLAMF7 promotes TCRαβ+ double negative T cell antitumor activity through enhancing glutamine metabolism	32
Radiotherapy resistance driven by Asparagine endopeptidase through ATR pathway modulation in breast cancer	32
CDKL1 potentiates the antitumor efficacy of radioimmunotherapy by binding to transcription factor YBX1 and blocking PD-L1 expression in lung cancer	32
TrkA promotes MDM2-mediated AGPS ubiquitination and degradation to trigger prostate cancer progression	32
Targeting PRMT5 through PROTAC for the treatment of triple-negative breast cancer	32
CDKN2A deletion is associated with immune desertification in diffuse pleural mesothelioma	32
Gemcitabine-induced β4 integrin drives cancer progression and gemcitabine resistance in pancreatic cancer	32
DCAF1 interacts with PARD3 to promote hepatocellular carcinoma progression and metastasis by activating the Akt signaling pathway	32
From ductal carcinoma in situ to invasive breast cancer: the prognostic value of the extracellular microenvironment	32
Correction: Nanovaccines with ferroptosis, necroptosis and STING-activation for synergistic immunotherapy	32